Marion Deslandres

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

J.E. Kurtz, Anne‐Claire Hardy‐Bessard, Marion Deslandres et al. · Gynecologic Oncology · 2009 · 85 citations

Advanced Cervical Cancer, Cervical Cancer Management, Cervical Cancer +8

Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes

Corinne Frère, Barbara Bournet, Sophie Gourgou et al. · Gastroenterology · 2019 · 85 citations · Full text

Thrombosis, Pulmonary Embolism, Surgical Oncology +9

Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers

Élodie Chantalat, Fabien Vidal, Pierre Lèguevaque et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 2015 · 26 citations

French Centers, Cervical Cancer Management, Cervical Cancer +12

A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer

Jaafar Bennouna, Marion Deslandres, Hélène Senellart et al. · Investigational New Drugs · 2014 · 25 citations

Medicine, Pharmacology, Colorectal Cancer +5

Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer

Sarah Bétrian, Martina Aida Ángeles, Antonio Gil Moreno et al. · International Journal of Gynecological Cancer · 2022 · 14 citations · Full text